LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor

OncoAlert and ecancer ASCO roundup - Day 3

OncoAlert and ecancer ASCO roundup - Day 2

OncoAlert and ecancer ASCO roundup - Day 1

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma

European Cancer Organisation - Time to Act

European Cancer Organisation: Time To Act

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

SMMART Program: A multi-omics tumour board with a focus on breast cancer

PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma

Clinical validation of a targeted methylation-based multi-cancer early detection test